Opinion: Hospital CEOs, med school leaders shouldn’t sit on for-profit health care company boards
In late July, Dr. Elizabeth Nabel, president of Harvard-affiliated Brigham and Women’s Hospital, came under intense scrutiny for activities she undertook outside her role at the hospital. The focus was on her sitting on the boards of directors of two publicly traded companies: Medtronics, a medical device company, and Moderna, a Boston-based biotech whose Covid-19 vaccine is now in clinical trials — and the Brigham is one of the testing sites for it.
As the Boston Globe was preparing to publish its first story on this conflict of interest, Nabel resigned from Moderna’s board and reportedly sold Moderna stock worth more than $6 million.
